네오이뮨텍

950220KOSDAQ

47.0 / 100

Reference Date: 2026-10-23

Financial Score18.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 15.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Neoimmune Tech is a biotech company specializing in T cell-based immunotherapy, with NT-I7, a long-acting T cell booster, as its core pipeline. The company is developing treatments for Acute Radiation Syndrome (ARS) and CAR-T combination therapies, while also holding an exclusive North American license for Endari®, an FDA-approved sickle cell disease treatment, to drive commercialization.

Number of Employees

40people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-64.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

3.63Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.6% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -62.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (47%)

Current 1,647Won52-week high 3,05052-week low 384

1-month return0.0Point

1m -15.67% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral[기재정정]반기보고서 (2026.06)2026-10-02